Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Todd Michael Bauer"'
Autor:
Sun Young Rha, Wilson H. Miller, María José de Miguel, Seock-Ah Im, Iwona Lugowska, Martin Wermke, Daisuke Kotani, Todd Michael Bauer, Atsuo Takashima, John Palcza, Marya F. Chaney, Konstantin Dobrenkov, Elena Garralda
Publikováno v:
Journal of Clinical Oncology. 41:394-394
394 Background: In the dose-confirmation phase of this multicohort trial (NCT02720068), the anti-LAG-3 antibody favezelimab had a manageable safety profile and promising antitumor activity in patients (pts) with advanced solid tumors, confirming prel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0ed6652ca5051b01a8428a166fab73
https://doi.org/10.1200/jco.2023.41.4_suppl.394
https://doi.org/10.1200/jco.2023.41.4_suppl.394
Autor:
Mrinal M. Gounder, Noboru Yamamoto, Manish R. Patel, Todd Michael Bauer, Patrick Schöffski, Rolf Grempler, Sara Durland-Busbice, Junxian Geng, Angela Maerten, Patricia LoRusso
Publikováno v:
Journal of Clinical Oncology. 40:3004-3004
3004 Background: The highly potent MDM2–p53 antagonist BI 907828 showed antitumor efficacy in vivo, particularly in TP53 wild-type, MDM2-amplified de-differentiated LPS (DDLPS) patient-derived xenografts and syngeneic models. This phase I study (NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e60aa9e0e08ddb7c7ca1d290d7b2adc5
https://doi.org/10.1200/jco.2022.40.16_suppl.3004
https://doi.org/10.1200/jco.2022.40.16_suppl.3004
Autor:
Benjamin J. Solomon, Todd Michael Bauer, Enriqueta Felip, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Konstantin K. Laktionov, Fiona Helen Blackhall, Elisa Dall’O, Anna Polli, Francesca Toffalorio, Tony S. K. Mok
Publikováno v:
Journal of Clinical Oncology. 40:9069-9069
9069 Background: Lorlatinib, a brain-penetrant, third generation ALK tyrosine kinase inhibitor (TKI), demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs crizotinib in a phase 3 study in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da62bafb20fa83faae87b23baec78a2
https://doi.org/10.1200/jco.2022.40.16_suppl.9069
https://doi.org/10.1200/jco.2022.40.16_suppl.9069
Autor:
Nathan A. Pennell, Lori J. Wirth, Justin F. Gainor, Julia K Rotow, Melissa Lynne Johnson, Todd Michael Bauer, Matthias Kroiss, Vineeth Sukrithan, Hyunseok Kang, Francis P. Worden, Christine M. Bestvina, Julien Hadoux, Philippe Alexandre Cassier, Antoine Italiano, Juergen Wolf, Marcia S. Brose, Emin Avsar, Michael D. Axelson, Vivek Subbiah, Alexander E. Drilon
Publikováno v:
Journal of Clinical Oncology. 40:TPS8595-TPS8595
TPS8595 Background: RET fusions are found in 1-2% of lung adenocarcinomas and 10-20% of papillary thyroid carcinomas. Activating RET mutations occur in 50-60% of medullary thyroid cancers (MTCs). Selpercatinib was the first selective RET inhibitor ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07afb7316f55a135d9d30e69eca73b6f
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8595
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8595
Autor:
Mark R. Middleton, Omid Hamid, Alexander Noor Shoushtari, Friedegund Elke Meier, Todd Michael Bauer, April K.S. Salama, John M. Kirkwood, Paolo Antonio Ascierto, Paul Lorigan, Cornelia Mauch, Marlana M. Orloff, T.R. Jeffry Evans, Shaad Essa Abdullah, Yuan Yuan, James Mitchell, Jessica Cecile Hassel
Publikováno v:
Journal of Clinical Oncology. 40:104-104
104 Background: Tebe is a T-cell receptor bispecific (gp100 x CD3) against gp100 peptide-HLA-A2 complexes that are overexpressed in uveal (UM)/cutaneous melanoma (CM). Tebe is the only therapy to show an OS benefit (HR 0.51) in a phase (Ph) 3 trial i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d34f10d95e5d18760102d0daaeb06f9f
https://doi.org/10.1200/jco.2022.40.16_suppl.104
https://doi.org/10.1200/jco.2022.40.16_suppl.104
Autor:
Eric Jonasch, Todd Michael Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, Ananya Roy, Yanfang Liu, Rodolfo F. Perini, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 40:4509-4509
4509 Background: Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in RCC. Antitumor activity of the HIF-2α inhibitor belzutifan has been observed in RCC and is approved for treatment in patients (pts) with VHL disease who require the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48cadcef5d46dee242a56bb14dc318ee
https://doi.org/10.1200/jco.2022.40.16_suppl.4509
https://doi.org/10.1200/jco.2022.40.16_suppl.4509
Autor:
Toni K. Choueiri, Todd Michael Bauer, David F. McDermott, Edward Arrowsmith, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi
Publikováno v:
Journal of Clinical Oncology. 39:272-272
272 Background: Belzutifan (MK-6482) inhibits HIF-2α and demonstrated antitumor activity and favorable safety as monotherapy in a phase 1 study of patients (pts) with metastatic ccRCC. Current study (NCT03634540) investigates belzutifan plus cabozan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd1e70c769772734c2f0e76ee7cc9477
https://doi.org/10.1200/jco.2021.39.6_suppl.272
https://doi.org/10.1200/jco.2021.39.6_suppl.272
Autor:
Omid Hamid, Todd Michael Bauer, Alexander I. Spira, Anthony J. Olszanski, Sandip Pravin Patel, Jeffrey S. Wasser, David C. Smith, Ani Sarkis Balmanoukian, Charu Aggarwal, Emmett V. Schmidt, Yufan Zhao, Hema Gowda, Tara C. Gangadhar
Publikováno v:
Journal of Clinical Oncology. 35:6010-6010
6010 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that induces immune tolerance by T-cell suppression. IDO1 overexpression has been associated with poor survival in SCCHN. Epacadostat (E) is a potent, selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b604b0a1da9b1ed0de3feeb32988a4d3
https://doi.org/10.1200/jco.2017.35.15_suppl.6010
https://doi.org/10.1200/jco.2017.35.15_suppl.6010
Autor:
Sarina Anne Piha-Paul, Cinta Hierro, Valentina Boni, Victor Moreno, Noah M. Hahn, Rhonda L. Bitting, Todd Michael Bauer, Rahul Raj Aggarwal, Steven Gourlay, Patrick Smith, Eleni Venetsanakos, Funda Meric-Bernstam, Ken Brameld, Dane Karr, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 35:TPS2616-TPS2616
TPS2616 Background: FGFR inhibition is a promising and clinically proven therapeutic approach in a number of solid tumors where genetic alterations of FGFR drive oncogenesis. PRN1371 is a highly selective oral, irreversible inhibitor of FGFR1-4 that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a258faf5f93da0a4253c67b12002856f
https://doi.org/10.1200/jco.2017.35.15_suppl.tps2616
https://doi.org/10.1200/jco.2017.35.15_suppl.tps2616
Autor:
Gary K. Schwartz, Douglas Adkins, Rebecca Suk Heist, Maura Abbott, Stephanie L. Barber, Richard C. Chao, Saskia T.C. Neuteboom, Isan Chen, James Christensen, Todd Michael Bauer
Publikováno v:
Journal of Clinical Oncology. 33:TPS2621-TPS2621
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c5bc837734668617bc552855efaedaa
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2621
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2621